Pfizer apologizes to U.K. docs as Lyrica protection campaign hits snag

Pfizer's ($PFE) bid to protect its pain drug Lyrica (pregabalin), which has lost some patent protection in the U.K., has had some unintended side effects. A recent court judgment--which said doctors must only prescribe the brand for neuropathic pain, an indication covered by a method patent--forced physicians to reissue prescriptions for the drug. The company has now apologized for "causing GPs concern" about the scripts, citing "discussion and media reporting" about the case. Report

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.